重新构想未分化甲状腺癌的治疗策略:通往治愈的路线图
本文综述未分化甲状腺癌(ATC)治疗进展,指出BRAFV600E突变患者经BRAF/MEK抑制剂可快速缩小肿瘤但疗效短暂,而无该突变者现有治疗疗效甚差;作者提出将急性淋巴细胞白血病的「全治疗」模式(诱导、巩固、维持)应用于ATC,整合靶向联合免疫、手术、放疗及数年系统治疗以清除残留癌细胞。
要点
- BRAFV600E突变ATC患者经BRAF/MEK抑制剂可快速显著缩瘤,但若不追加其他治疗则缓解短暂。
- 无BRAFV600E突变者现有治疗疗效远逊于突变患者。
- 作者提出借鉴急性淋巴细胞白血病「全治疗」框架,对ATC实施诱导、巩固与维持治疗。
核心结论
- 作者提出将自20世纪60年代用于急性淋巴细胞白血病的「全治疗」模式(诱导、巩固、维持)应用于未分化甲状腺癌(ATC),整合靶向联合免疫治疗、手术、放疗及持续数年的系统治疗以尝试根除所有残留ATC细胞。
研究设计与样本
- 本文为综述,回顾相关文献并提出将「全治疗」模式应用于ATC的治疗框架。
主要发现
- BRAFV600E突变ATC患者经BRAF/MEK抑制剂治疗可快速且显著缩小肿瘤,但除非追加其他治疗手段,否则这些缓解短暂。
- 无BRAFV600E突变的ATC患者,当前可用治疗疗效远逊。
- 作者将诱导、巩固、维持的概念 adapted 应用于ATC,整合靶向联合免疫的系统治疗、手术、放疗及持续数年的系统治疗。
临床怎么用
- 作者提出对ATC患者应基于基因组学紧急治疗,而非仅提供姑息治疗。
- 作者提出的「全治疗」方案包括:靶向联合免疫的系统治疗、手术、放疗,以及持续数年的系统治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Anaplastic thyroid cancer (ATC) is an aggressive cancer that leads to rapid death if left untreated. However, recent advances in ATC treatment have dramatically changed the prognosis in a select group of patients with BRAFV600E mutations. In these patients, BRAF/MEK inhibitors have been shown to dramatically and rapidly shrink tumors. Yet, these responses are short-lived unless additional treatment modalities are applied. In patients without a BRAFV600E mutation, the current available therapies are far less effective. Summary: In this article, we review the relevant literature and propose applying the "Total Therapy" approach used since the 1960s for another deadly but curable disease, acute lymphocytic leukemia, to ATC. We have adapted the concepts of Induction, Consolidation, and Maintenance, applying them to ATC. This regimen integrates the treatments we have found to be successful in ATC: combination systemic therapy using targeted therapy plus immunotherapy, surgery, radiation, and continuation of the systemic therapy for several years, thereby attempting to eradicate all residual ATC cells. Conclusions: There has been a renewed interest in understanding the genomics of ATC and treating these patients with urgency rather than just providing palliative care. This shift has led to significant improvements in the prognosis of ATC. With the right tools and a clear roadmap to guide us, we now aim to take on the challenge of curing these patients.
引用
- Cabanillas ME, Akhave N, Banuchi V, et al. Reimagining the Therapeutic Approach for Anaplastic Thyroid Cancer: The Roadmap to a Cure. Thyroid. 2025. PMID: 40388579. doi:10.1089/thy.2025.0044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。